[go: up one dir, main page]

WO2002004514A3 - Compositions et procedes pour le traitement et le diagnostic du cancer du poumon - Google Patents

Compositions et procedes pour le traitement et le diagnostic du cancer du poumon Download PDF

Info

Publication number
WO2002004514A3
WO2002004514A3 PCT/US2001/022058 US0122058W WO0204514A3 WO 2002004514 A3 WO2002004514 A3 WO 2002004514A3 US 0122058 W US0122058 W US 0122058W WO 0204514 A3 WO0204514 A3 WO 0204514A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
diagnosis
lung cancer
therapy
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/022058
Other languages
English (en)
Other versions
WO2002004514A8 (fr
WO2002004514A2 (fr
Inventor
Tongtong Wang
Yoshihiro Watanabe
Robert A Henderson
Jeffrey C Johnson
Marc W Retter
Margarita Durham
Darrick Carter
Gary Richard Fanger
Thomas S Vedvick
Chaitanya S Bangur
Andria Mcnabb
Aijun Wang
Neil Fanger
Ann Switzer
Patricia D Mcneill
Jonathan D Clapper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/614,124 external-priority patent/US6630574B1/en
Priority claimed from US09/651,563 external-priority patent/US6914132B1/en
Priority claimed from US09/658,824 external-priority patent/US6746846B1/en
Priority claimed from US09/671,325 external-priority patent/US6667154B1/en
Priority claimed from US09/702,705 external-priority patent/US6504010B1/en
Priority claimed from US09/736,457 external-priority patent/US6509448B2/en
Priority claimed from US09/849,626 external-priority patent/US20020197669A1/en
Priority to CA002415544A priority Critical patent/CA2415544A1/fr
Priority to JP2002509377A priority patent/JP2004512824A/ja
Priority to AU2002218770A priority patent/AU2002218770A1/en
Priority to EP01984164A priority patent/EP1343886A2/fr
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of WO2002004514A2 publication Critical patent/WO2002004514A2/fr
Publication of WO2002004514A8 publication Critical patent/WO2002004514A8/fr
Anticipated expiration legal-status Critical
Publication of WO2002004514A3 publication Critical patent/WO2002004514A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des procédés pour le traitement et le diagnostic du cancer, en particulier du cancer du poumon. Les compositions typiques comprennent un ou plusieurs polypeptides de tumeur pulmonaire, des parties immunogènes de ceux-ci, des polynucléotides qui codent pour ces polypeptides, une cellules présentatrice d'antigène qui exprime ces polypeptides, et des lymphocytes T spécifiques de cellules exprimant ces polypeptides. Les compositions décrites sont utiles, par exemple, dans le diagnostic, la prévention et/ou le traitement de maladies, en particulier le cancer du poumon.
PCT/US2001/022058 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon Ceased WO2002004514A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01984164A EP1343886A2 (fr) 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
AU2002218770A AU2002218770A1 (en) 2000-07-11 2001-07-10 Compositions and methods for the therapy and diagnosis of lung cancer
JP2002509377A JP2004512824A (ja) 2000-07-11 2001-07-10 肺癌の治療および診断のための組成物および方法
CA002415544A CA2415544A1 (fr) 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US09/614,124 2000-07-11
US09/614,124 US6630574B1 (en) 1999-06-30 2000-07-11 Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 US6914132B1 (en) 1999-06-30 2000-08-29 Compositions and methods for the therapy and diagnosis of lung cancer
US09/651,563 2000-08-29
US09/658,824 2000-09-08
US09/658,824 US6746846B1 (en) 1999-06-30 2000-09-08 Methods for diagnosing lung cancer
US09/671,325 US6667154B1 (en) 1999-06-30 2000-09-26 Compositions and methods for the therapy and diagnosis of lung cancer
US09/671,325 2000-09-26
US67741900A 2000-10-06 2000-10-06
US09/677,419 2000-10-06
US09/702,705 2000-10-30
US09/702,705 US6504010B1 (en) 1999-06-30 2000-10-30 Compositions and methods for the therapy and diagnosis of lung cancer
US09/736,457 US6509448B2 (en) 1999-06-30 2000-12-13 Compositions and methods for the therapy and diagnosis of lung cancer
US09/736,457 2000-12-13
US09/849,626 2001-05-03
US09/849,626 US20020197669A1 (en) 2000-12-13 2001-05-03 Compositions and methods for the therapy and diagnosis of lung cancer

Publications (3)

Publication Number Publication Date
WO2002004514A2 WO2002004514A2 (fr) 2002-01-17
WO2002004514A8 WO2002004514A8 (fr) 2002-12-27
WO2002004514A3 true WO2002004514A3 (fr) 2003-06-19

Family

ID=27575493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022058 Ceased WO2002004514A2 (fr) 2000-07-11 2001-07-10 Compositions et procedes pour le traitement et le diagnostic du cancer du poumon

Country Status (6)

Country Link
EP (1) EP1343886A2 (fr)
JP (1) JP2004512824A (fr)
AR (1) AR031250A1 (fr)
AU (1) AU2002218770A1 (fr)
CA (1) CA2415544A1 (fr)
WO (1) WO2002004514A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
EP1666495A1 (fr) * 1999-12-01 2006-06-07 Genentech, Inc. Polypeptides secretés et transmembranaires et acides nucléiques les codant
US20030166300A1 (en) * 2000-08-30 2003-09-04 Tang Y. Tom Growth-related inflammatory and immune response protein
ZA200204907B (en) 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
EP1543018A4 (fr) * 2002-08-14 2006-10-25 Lg Life Sciences Ltd Familles de genes associees au cancer du foie
US20060258574A1 (en) * 2002-09-26 2006-11-16 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
US7449291B1 (en) 2003-01-13 2008-11-11 University Of Washington Methods for identifying subjects susceptible to Charcot-Marie-Tooth neuropathy type 1C
WO2004070058A1 (fr) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methodes et compositions permettant de prevoir, diagnostiquer, pronostiquer, prevenir et traiter des broncho-pneumopathies chroniques obstructives
JP2006521110A (ja) * 2003-03-24 2006-09-21 コリクサ コーポレイション 肺癌の検出およびモニタリング
JP4643450B2 (ja) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
EP1668354A2 (fr) * 2003-09-24 2006-06-14 Oncotherapy Science, Inc. Methode de diagnostic du cancer du sein
JP4428995B2 (ja) 2003-12-03 2010-03-10 関東化学株式会社 金属膜のエッチング液組成物
JP2008507261A (ja) * 2004-01-27 2008-03-13 コンピュゲン ユーエスエイ，インク． 肺癌診断のための新規のヌクレオチド配列およびアミノ酸配列、ならびにそのアッセイおよび使用方法
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8940488B2 (en) 2004-03-31 2015-01-27 Hiroyuki Aburatani Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
EP1744162B1 (fr) 2004-03-31 2010-08-04 Hiroyuki Aburatani Diagnostic du cancer et traitement utilisant l'anticorps anti-robo1
JP5150855B2 (ja) * 2005-07-29 2013-02-27 オンコセラピー・サイエンス株式会社 Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法
AU2006351974A1 (en) * 2006-12-21 2008-06-26 Intradigm Corporation Inhibitory polynucleotide compositions and methods for treating cancer
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
KR101610353B1 (ko) * 2007-08-20 2016-04-07 온코세라피 사이언스 가부시키가이샤 Ｃｄｃａ１ 펩티드 및 이를 포함하는 약학적 조성물
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2010134601A1 (fr) * 2009-05-22 2010-11-25 国立大学法人岡山大学 Peptide induisant une réponse immunitaire spécifique contre xage-1b et son utilisation
US9687538B2 (en) * 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
CN114102955B (zh) * 2020-08-31 2024-05-07 天津科技大学 一种采用常温发泡技术制备发泡聚乳酸的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038973A2 (fr) * 1998-01-28 1999-08-05 Corixa Corporation Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
WO2000055375A1 (fr) * 1999-03-17 2000-09-21 Alphagene, Inc. Proteines secretees et polynucleotides les codant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10139800A (ja) * 1996-11-15 1998-05-26 Santen Pharmaceut Co Ltd シェーグレン症候群治療剤
CZ20014718A3 (cs) * 1999-06-30 2003-01-15 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038973A2 (fr) * 1998-01-28 1999-08-05 Corixa Corporation Composes destines au diagnostic et a la therapie du cancer du poumon et procedes d'utilisation associes
WO2000055375A1 (fr) * 1999-03-17 2000-09-21 Alphagene, Inc. Proteines secretees et polynucleotides les codant

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN S-L ET AL: "Isolation and characterizaton of a novel gene expressed in multiple cancers", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, no. 4, 15 February 1996 (1996-02-15), pages 741 - 751, XP002106655, ISSN: 0950-9232 *
DATABASE EMBL [online] 1 July 1997 (1997-07-01), "ab23f06.r1 Stratagene lung (#937210) Homo sapiens cDNA clone", XP002199797, Database accession no. AA488696 *
DATABASE EMBL [online] 5 March 1995 (1995-03-05), XP002199799, Database accession no. T63732.1 *
DATABASE EMBL [online] 7 June 2000 (2000-06-07), "Homo sapiens cDNA", XP002199798, Database accession no. AW950090 *
GÜRE ET AL: "Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, 1 March 1998 (1998-03-01), pages 1034 - 1041, XP002103188, ISSN: 0008-5472 *
HILLIER L ET AL: "GENERATION AND ANALYSIS OF 280,000 HUMAN EXPRESSED SEQUENCE TAGS", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 6, 1996, pages 807 - 828, XP002942261, ISSN: 1088-9051 *
ZANGEMEISTER-WITTKE U ET AL: "REVIEW NOVEL APPROACHES TO THE TREATMENT OF SMALL-CELL LUNG CANCER", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, BASEL, CH, vol. 55, no. 12, September 1999 (1999-09-01), pages 1585 - 1598, XP000960960, ISSN: 1420-682X *

Also Published As

Publication number Publication date
AU2002218770A1 (en) 2002-01-21
WO2002004514A8 (fr) 2002-12-27
EP1343886A2 (fr) 2003-09-17
CA2415544A1 (fr) 2002-01-17
WO2002004514A2 (fr) 2002-01-17
JP2004512824A (ja) 2004-04-30
AR031250A1 (es) 2003-09-17

Similar Documents

Publication Publication Date Title
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2001092581A3 (fr) Compositions et methodes permettant le traitement et le diagnostic du cancer de l'ovaire
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2002074156A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2001051633A3 (fr) Compositions et methodes destinees au traitement et au diagnostique du cancer de la prostate
WO2002089747A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2004052276A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer de la prostate
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002016413A3 (fr) Vaccins
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2002014503A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers associes a her-2/neu
WO2002012328A8 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2002058534A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2003037267A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2002078516A3 (fr) Compositions et methodes de traitement et de diagnostic de cancers
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon
WO2003013431A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du sein
WO2002039885A3 (fr) Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2002012280A3 (fr) Compositions et procedes pour le diagnostic et le traitement du cancer du colon
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2006031363A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du poumon
WO2005051990A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du sein
WO2003086175A8 (fr) Compositions et procedes destines au traitement et au diagnostic du cancer du poumon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWE Wipo information: entry into national phase

Ref document number: 2415544

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001984164

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001984164

Country of ref document: EP